ArticleVaccine2021
How should we conduct pandemic vaccination?
Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Having a real say: findings from first nations community panels on pandemic influenza vaccine distribution.BMC public health · 2023Article
- Role of Trust, Risk Perception, and Perceived Benefit in COVID-19 Vaccination Intention of the Public.Healthcare (Basel, Switzerland) · 2023Article
- Review
- Designing an optimization model for the vaccine supply chain during the COVID-19 pandemic.Expert systems with applications · 2023Article
- Multimorbidity and SARS-CoV-2-Related Outcomes: Analysis of a Cohort of Italian Patients.JMIR public health and surveillance · 2023Article
- Article
- Monkeypox: Emerging virus of concern; antivirals and vaccines therapeutic options.Microbial pathogenesis · 2022Review
- Prioritization of COVID-19 vaccination. The added value of the "VALIDATE" approach.Health policy (Amsterdam, Netherlands) · 2022Review
- Exploring the ethics of genetic prioritisation for COVID-19 vaccines.European journal of human genetics : EJHG · 2022Review
- Rifampicin for COVID-19.World journal of virology · 2022Review
- Disease burden and vaccination priorities in Colombia.Vaccine · 2022Article
- COVID-19 vaccines for children and adolescents in Africa: aligning our priorities to situational realities.BMJ global health · 2022Review
- Motivation for COVID-19 Vaccination in Priority Occupational Groups: A Cross-Sectional Survey.International journal of environmental research and public health · 2021Article
- COVID-19 pandemics Stage II - Energy and environmental impacts of vaccination.Renewable & sustainable energy reviews · 2021Review
- A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures.EClinicalMedicine · 2021Article
- Variability in Forest Visit Numbers in Different Regions and Population Segments before and during the COVID-19 Pandemic.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination plays an important role in pandemic planning and response. The possibility of developing an effective vaccine for a novel pandemic virus is not assured. However, as we have seen with SARS-CoV-2 vaccine development, with sufficient resources and global focus, successful outcomes can be achieved in a relatively short period. However even when vaccine is available it will initially be scarce. When one becomes available, how should it be distributed? In this paper we explicate how ethical thinking that is carefully attuned to context is essential to decisions about how we should conduct vaccination in a pandemic where demand exceeds supply. We focus on two key issues. First, setting the aims for a pandemic vaccination programme. Second, thinking about the means of delivering a chosen aim. We outline how pandemic vaccine distribution strategies can be implemented with distinct aims, e.g. protecting groups at greater risk of harm, saving the most lives, or ensuring societal benefit. Each aim will result in a focus on a different priority population and each strategy will have a different benefit-harm profile. Once we have decided our aim, we still have choices to make about delivery. We may achieve at least some ends via direct or indirect strategies. Such policy decisions are not merely technical, but necessarily involve ethics. One important general issue is that such planning decisions about distribution will always be made under conditions of uncertainty about vaccine safety and effectiveness. However, planning how to distribute vaccine for SARS-CoV-2 is even harder because we understand relatively little about the virus, transmission, and its immunological impact in the short and long term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.